Among the 21,435 patients with metastatic disease at any site (bone, lung, liver, brain), 50.9%, 13.4%, 7.3%, 11.5% and 16.9% had HR+/HER2−, HR+/HER2+, HR−/HER2+, triple-negative and unknown subtype, respectively. This evidence concerns the gene ERBB2 and metastatic neoplasm.